

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

Claims 1-6: CANCELED

Claim 7. **(Currently Amended)** A method of evaluating the effectiveness of an antiviral therapy of an HIV-infected patient comprising:

- (i) collecting a sample from an HIV-infected patient;
- (ii) determining ~~whether the in said sample comprises at least one nucleic acid chosen from each of the following nucleic acids:~~

(a) a first nucleic acid encoding HIV reverse transcriptase comprising at least one mutation chosen from:

- 1) ~~at least one mutation chosen from~~ 88E, 101H, 101N, 101P, 101Q, 101T, 103H, 103S, 179I, 179E, 181V, 190E, 190S, ~~and~~ or 190T,
- 2) mutations 103 R and 179D, or
- 3) combinations of 1) and 2),

in which the presence of said at least one mutation correlates with resistance to at least one Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI);

(b) a second nucleic acid encoding HIV reverse transcriptase comprising at least one mutation chosen from 69S-[S-S], 184G, 184L, 215V, 44D, 44A, and 118I,

in which the presence of said at least one mutation correlates with resistance to at least one Nucleoside Reverse Transcriptase Inhibitor (NRTI); and

(c) a third nucleic acid encoding HIV protease [having] comprising at least one mutation chosen from:

- 1) 88T, or
- 2) mutations 33F and 90M, or
- 3) combinations of 1) and 2),

in which the presence of said at least one mutation correlates with resistance to at least one Protease Inhibitor (PI); and

~~(iii) using the presence of said at least one nucleic acid to evaluate the effectiveness of said antiviral therapy~~

DOCKET NO.: TIBO-0016  
Application No.: 09/580,491  
Office Action Dated: August 26, 2003

PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 CFR § 1.116

(d) wherein the antiviral therapy includes nucleoside reverse transcriptase inhibitors (NRTIs) which are one or more drugs of the group selected from zidovudine (ZDV), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC) and abacavir (ABC); non-nucleoside reverse transcriptase inhibitors (NNRTIs) which are one or more drugs of the group selected from nevirapine (NVP), delavirdine (DLV) and efavirenz; and protease inhibitors (PIs) which are one or more drugs of the group selected from saquinavir (SQV), ritonavir (RTV), indinavir (IDV) nelfinavir (NFV), amprenavir (APV) and ABT-378.

Claims 8-30: CANCELED